283 related articles for article (PubMed ID: 30678059)
1. Antigenic Targets for the Immunotherapy of Acute Myeloid Leukaemia.
Khan GN; Orchard K; Guinn BA
J Clin Med; 2019 Jan; 8(2):. PubMed ID: 30678059
[TBL] [Abstract][Full Text] [Related]
2. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia.
Smits EL; Lee C; Hardwick N; Brooks S; Van Tendeloo VF; Orchard K; Guinn BA
Cancer Immunol Immunother; 2011 Jun; 60(6):757-69. PubMed ID: 21519825
[TBL] [Abstract][Full Text] [Related]
4. A Direct Comparison, and Prioritisation, of the Immunotherapeutic Targets Expressed by Adult and Paediatric Acute Myeloid Leukaemia Cells: A Systematic Review and Meta-Analysis.
Morris VS; Ghazi H; Fletcher DM; Guinn BA
Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298623
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapy of myeloid leukaemia.
Guinn BA; Mohamedali A; Thomas NS; Mills KI
Cancer Immunol Immunother; 2007 Jul; 56(7):943-57. PubMed ID: 17180671
[TBL] [Abstract][Full Text] [Related]
6. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.
Versluis J; Hazenberg CL; Passweg JR; van Putten WL; Maertens J; Biemond BJ; Theobald M; Graux C; Kuball J; Schouten HC; Pabst T; Löwenberg B; Ossenkoppele G; Vellenga E; Cornelissen JJ;
Lancet Haematol; 2015 Oct; 2(10):e427-36. PubMed ID: 26686044
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine.
Cheuk AT; Guinn BA
Front Biosci; 2008 Jan; 13():2022-9. PubMed ID: 17981688
[TBL] [Abstract][Full Text] [Related]
8. Acute leukaemia: development, remission/relapse pattern, relationship between normal and leukaemic haemopoiesis, and the 'sleeper-to-feeder' stem cell hypothesis.
Killmann SA
Baillieres Clin Haematol; 1991 Jul; 4(3):577-98. PubMed ID: 1958881
[TBL] [Abstract][Full Text] [Related]
9. New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.
Jordaens S; Cooksey L; Freire Boullosa L; Van Tendeloo V; Smits E; Mills KI; Orchard KH; Guinn BA
Cancer Immunol Immunother; 2020 May; 69(5):867-877. PubMed ID: 31970440
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell-based immunotherapy in myeloid leukaemia: translating fundamental mechanisms into clinical applications.
van de Loosdrecht AA; van den Ancker W; Houtenbos I; Ossenkoppele GJ; Westers TM
Handb Exp Pharmacol; 2009; (188):319-48. PubMed ID: 19031033
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.
Acheampong DO; Adokoh CK; Asante DB; Asiamah EA; Barnie PA; Bonsu DOM; Kyei F
Biomed Pharmacother; 2018 Jan; 97():225-232. PubMed ID: 29091870
[TBL] [Abstract][Full Text] [Related]
12. Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.
Nahas MR; Stroopinsky D; Rosenblatt J; Cole L; Pyzer AR; Anastasiadou E; Sergeeva A; Ephraim A; Washington A; Orr S; McMasters M; Weinstock M; Jain S; Leaf RK; Ghiasuddin H; Rahimian M; Liegel J; Molldrem JJ; Slack F; Kufe D; Avigan D
Br J Haematol; 2019 May; 185(4):679-690. PubMed ID: 30828801
[TBL] [Abstract][Full Text] [Related]
13. [Biological properties and sensitivity to induction therapy of differentiated cells expressing atypical immunophenotype in acute leukemia of children].
Pituch-Noworolska A
Folia Med Cracov; 2001; 42(3):5-80. PubMed ID: 12353422
[TBL] [Abstract][Full Text] [Related]
14. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?
Riley CL; Mathieu MG; Clark RE; McArdle SE; Rees RC
Cancer Immunol Immunother; 2009 Sep; 58(9):1489-99. PubMed ID: 19259670
[TBL] [Abstract][Full Text] [Related]
15. Acute myeloid leukaemia and the immune system: implications for immunotherapy.
Barrett AJ
Br J Haematol; 2020 Jan; 188(1):147-158. PubMed ID: 31782805
[TBL] [Abstract][Full Text] [Related]
16. Post-consolidation immunotherapy with histamine dihydrochloride and interleukin-2 in AML.
Romero AI; Thorén FB; Aurelius J; Askarieh G; Brune M; Hellstrand K
Scand J Immunol; 2009 Sep; 70(3):194-205. PubMed ID: 19703009
[TBL] [Abstract][Full Text] [Related]
17. Microarray analysis of tumour antigen expression in presentation acute myeloid leukaemia.
Guinn BA; Gilkes AF; Woodward E; Westwood NB; Mufti GJ; Linch D; Burnett AK; Mills KI
Biochem Biophys Res Commun; 2005 Aug; 333(3):703-13. PubMed ID: 15963951
[TBL] [Abstract][Full Text] [Related]
18. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
19. Long-term marrow cultures: in vitro purging of leukaemic cells.
Chang J; Dexter TM
Baillieres Clin Haematol; 1991 Jul; 4(3):775-88. PubMed ID: 1958891
[TBL] [Abstract][Full Text] [Related]
20. Sub-clonal analysis of the murine C1498 acute myeloid leukaemia cell line reveals genomic and immunogenic diversity.
Driss V; Leprêtre F; Briche I; Mopin A; Villenet C; Figeac M; Quesnel B; Brinster C
Immunol Lett; 2017 Dec; 192():27-34. PubMed ID: 29030252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
